PNEUMOSTEM

Phase 2Biologic

MMedipost Co Ltd.

PNEUMOSTEM is one of 140 biologic programs targeting Bronchopulmonary Dysplasia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

139

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchopulmonary DysplasiaActive, not recruiting

Pulmonary Arterial HypertensionNot yet recruiting

Safety and EfficacyActive, not recruiting

Efficacy and SafetyActive, not recruiting

Bronchopulmonary DysplasiaPreclinical

Active, not recruiting

Pulmonary Arterial HypertensionPhase 1

Not yet recruiting

Safety and EfficacyPhase 2

Active, not recruiting

Efficacy and SafetyPhase 2

Active, not recruiting

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Tuoyi

SSun Yat-sen University

Phase 3

4 2

Lutathera

Novartis

Phase 3

1 3

HLX10

Shanghai Henlius Biotech

Phase 3

2 4

PLB1004

AAvistone Biotechnology Co., Ltd.

Phase 3

1 5

NTQ5082

NNanjing Chia-tai Tianqing Pharmaceutical

Phase 3

1 6

S1,

CChinese Academy of Medical Sciences

Phase 3

1 7

VAY736

Novartis

Phase 3

2 8

HSK39297

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

3 9

TLL-018

HHangzhou Highlightll Pharmaceutical Co., Ltd

Phase 3

1 10

AVTX-803

AAUG Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Safety and Efficacy

NCT04003857

Q3 2027

Phase 1Not yet recruiting

Pulmonary Arterial Hypertension

NCT07368088

Clinical

Trials by Indication[1]

Safety and Efficacy3 trials

Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial

Active, not recruiting·MMedipost Co Ltd.·Phase 2·NCT04003857·60 enrolled

Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study

Completed·MMedipost Co Ltd.··NCT02023788·8 enrolled

Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial

Completed·MMedipost Co Ltd.·N/A·NCT01897987·62 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Pneumostem® for IVH in Premature Infants (Phase 2a)

Active, not recruiting·SSamsung Medical Center·Phase 2·NCT02890953·22 enrolled

Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants

Completed·MMedipost Co Ltd.·Phase 2·NCT01828957·69 enrolled

Hemorrhage1 trial

Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage

Completed·SSamsung Medical Center·Phase 1·NCT02274428·9 enrolled

Bronchopulmonary Dysplasia1 trial

Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia

Active, not recruiting·SSamsung Medical Center··NCT01632475·9 enrolled

Pulmonary Arterial Hypertension1 trial

PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension

Not yet recruiting·SSamsung Medical Center·Phase 1·NCT07368088·12 enrolled

1 more indication

Premature Infants1 trial

PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants

Completed·MMedipost Co Ltd.·Phase 2·NCT03392467·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for PNEUMOSTEM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PNEUMOSTEM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PNEUMOSTEM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medipost Co Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMedipost Co Ltd.

PNEUMOSTEM

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Safety and Efficacy3 trials

Efficacy and Safety2 trials

Hemorrhage1 trial

Bronchopulmonary Dysplasia1 trial

Pulmonary Arterial Hypertension1 trial

Premature Infants1 trial

References

Drug Info

Quick Facts

Related News